NEW YORK, March 9, 2018 /PRNewswire/ -- The multidistrict litigation recently established in the U.S. District Court, Eastern District of Kentucky, for all federally-filed product liability lawsuits involving Onglyza and Kombiglyze XR is moving forward, with the issuance of the proceeding's first Practice and Procedure Order earlier this month. (IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION, MDL No. 2809)
Among other things, the February 9th Order directs the parties in each case transferred to the Eastern District of Kentucky to submit to the Court a brief summary of their lawsuit addressing, among other things, the factual allegations put forth in the case, the legal issues involved, and any discovery that has been completed, including depositions that have been taken.
"Our Firm is representing a number of clients who developed heart failure and other cardiovascular complications allegedly related to treatment with Onglyza and Kombiglyze XR. We are pleased that this multidistrict litigation is moving forward and will continue to monitor the proceeding for any developments that could impact our clients' cases," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to individuals who were diagnosed with heart failure or other cardiovascular injuries following treatment with Onglyza or Kombiglyze XR.
Onglyza and Kombiglyze XR are prescription medications used to treat Type 2 diabetics. The U.S. Food & Drug Administration (FDA) approved Onglyza (saxagliptin) in 2009. Kombiglyze XR, a combination medication that contains saxagliptin and metformin, was approved the following year.
In April 2016, FDA ordered the manufacturers of Onglyza and Kombiglyze XR to add new information regarding a potential risk of heart failure to the "Warnings and Precautions" section of the drugs' labels. The agency acted after a clinical trial called SAVOR-TMI suggested that saxagliptin was associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality.
At least 84 Onglyza and Kombiglyze XR lawsuits are now pending in the federal multidistrict underway in Kentucky. Plaintiffs involved in this litigation claim that AstraZeneca and Bristol-Myers Squibb concealed information linking saxagliptin to an increased risk of heart failure and failed to warn doctors and patients about its alleged potential to cause cardiac arrest, congestive heart failure and death.
Type 2 diabetics who allegedly developed heart failure or other serious cardiovascular complications while using Onglyza or Kombiglyze XR could be entitled to compensation for medical bills, lost wages, pain and suffering and more. To obtain a free case evaluation, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP 10 East 40th Street New York, New York 10016 800-511-5092